tirzepatide recent news Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, (Zepbound). The device gives patients an additional, potentially more convenient option for taking the drug: They can Tirzepatide outperforms semaglutide in weight

Results were presented by Deborah B Horn, DO, MPH, medical director of the UT Physicians Center for Obesity Medicine and Metabolic Performance and clinical assistant professor at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), and Carel W le Roux, MBChB, MSC, FRCP, FRCPath, PhD, director of the Metabolic Medicine Group and Professor of Metabolic Medicine at Ulster University

Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript

Compounded tirzepatide consists of the same active ingredient found in the diabetes drug Mounjaro and the weight loss drug Zepbound

Applied and Environmental Microbiology

Rotating the injection site each time is also advised to mitigate skin irritation or soreness